In line with these findings, Hong et al. demonstrated that AML-derived EVs appeared to reduce the efficacy of NK-92 immunotherapy by transporting the inhibitory ligand (TGF-β1) to NKG2D, a surface-activating receptor for NK-92. The gene discussed is TGFB1; the disease is acute myeloid leukemia.